Summary
Merck & Co., Inc. (MRK) reported solid financial results for the quarter and six months ended June 30, 2011. The company demonstrated revenue growth driven by key pharmaceutical products and a favorable foreign exchange impact. Despite the growth, significant restructuring costs related to the integration of Schering-Plough continued to affect profitability. Net income saw a substantial increase year-over-year, largely due to a favorable tax settlement and other one-time items, though this needs to be viewed in context with the ongoing restructuring efforts. Investors should note the continued impact of patent expirations on certain established products, balanced by the growth in newer pharmaceuticals and a robust pipeline of development candidates. The company's financial position remains strong with substantial cash and investments.
Financial Highlights
50 data points| Revenue | $12.15B |
| Cost of Revenue | $4.28B |
| Gross Profit | $7.87B |
| R&D Expenses | $1.94B |
| SG&A Expenses | $3.52B |
| Interest Expense | $170.00M |
| Net Income | $2.02B |
| EPS (Basic) | $0.65 |
| EPS (Diluted) | $0.65 |
| Shares Outstanding (Basic) | 3.09B |
| Shares Outstanding (Diluted) | 3.11B |
Key Highlights
- 1Worldwide sales increased by 7% to $12.2 billion for the second quarter of 2011 compared to the prior year, driven by strong performance in key products like Januvia, Janumet, Remicade, and Singulair.
- 2Net income attributable to Merck & Co., Inc. increased significantly to $2.024 billion for the quarter, up from $752 million in the prior year, aided by a substantial tax benefit from a federal income tax audit settlement.
- 3Restructuring costs related to the merger integration remained significant, with $808 million incurred in the second quarter, reflecting ongoing efforts to optimize the combined company's cost structure.
- 4The company acquired Inspire Pharmaceuticals for approximately $420 million in May 2011, strengthening its ophthalmic product portfolio.
- 5Sales of the cardiovascular drugs Cozaar/Hyzaar and Fosamax declined significantly due to patent expirations, highlighting the ongoing challenge of generic competition.
- 6The company's R&D pipeline shows promising candidates, including Victrelis (approved for Hepatitis C) and Zoely (approved in the EU for contraception), indicating future growth drivers.
- 7Merck maintained a strong liquidity position with $16.2 billion in cash and investments at the end of the quarter.